Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
DGX

DGX - Quest Diagnostics Inc Stock Price, Fair Value and News

137.59USD+0.89 (+0.65%)Market Closed

Market Summary

DGX
USD137.59+0.89
Market Closed
0.65%

DGX Stock Price

View Fullscreen

DGX RSI Chart

DGX Valuation

Market Cap

14.3B

Price/Earnings (Trailing)

16.85

Price/Sales (Trailing)

1.54

EV/EBITDA

12.5

Price/Free Cashflow

15.05

DGX Price/Sales (Trailing)

DGX Profitability

Operating Margin

32.87%

EBT Margin

12.05%

Return on Equity

13.08%

Return on Assets

6.06%

Free Cashflow Yield

6.64%

DGX Fundamentals

DGX Revenue

Revenue (TTM)

9.3B

Rev. Growth (Yr)

1.5%

Rev. Growth (Qtr)

3.41%

DGX Earnings

Earnings (TTM)

846.0M

Earnings Growth (Yr)

-3.96%

Earnings Growth (Qtr)

1.04%

Breaking Down DGX Revenue

Last 7 days

8.4%

Last 30 days

6.4%

Last 90 days

5.7%

Trailing 12 Months

-6.1%

How does DGX drawdown profile look like?

DGX Financial Health

Current Ratio

0.97

Debt/Equity

0.59

Debt/Cashflow

0.35

DGX Investor Care

Dividend Yield

2.24%

Dividend/Share (TTM)

2.88

Buy Backs (1Y)

0.89%

Diluted EPS (TTM)

7.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.3B000
20239.6B9.5B9.3B9.3B
202210.7B10.6B10.3B9.9B
202110.3B11.1B11.0B10.8B
20207.7B7.5B8.4B9.4B
20197.5B7.6B7.6B7.7B
20187.5B7.5B7.6B7.5B
20177.5B7.4B7.4B7.4B
20167.5B7.5B7.5B7.5B
20157.5B7.6B7.5B7.5B
20147.2B7.3B7.4B7.4B
20137.3B7.2B7.2B7.1B
20127.5B7.5B7.5B7.4B
20117.4B7.4B7.4B7.4B
20107.5B7.4B7.4B7.4B
20097.3B7.3B7.4B7.5B
200806.9B7.1B7.2B
20070006.7B
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Quest Diagnostics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 26, 2024
delaney mark e
sold (taxes)
-21,778
128
-170
svp & chief commercial officer
Mar 26, 2024
plewman patrick
sold (taxes)
-14,604
128
-114
svp for diagnostic services
Feb 29, 2024
doherty catherine t.
sold
-149,420
125
-1,187
evp, regional businesses
Feb 29, 2024
prevoznik michael e
sold
-706,313
125
-5,611
svp & general counsel
Feb 28, 2024
plewman patrick
sold (taxes)
-42,077
126
-333
svp for diagnostic services
Feb 28, 2024
prevoznik michael e
sold (taxes)
-108,796
126
-861
svp & general counsel
Feb 28, 2024
samad sam
sold (taxes)
-82,892
126
-656
executive vice president & cfo
Feb 28, 2024
doherty catherine t.
sold
-703,350
126
-5,557
evp, regional businesses
Feb 28, 2024
delaney mark e
sold (taxes)
-28,431
126
-225
svp & chief commercial officer
Feb 28, 2024
davis j. e.
sold (taxes)
-634,327
126
-5,020
ceo and president

1–10 of 50

Which funds bought or sold DGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 23, 2024
WETZEL INVESTMENT ADVISORS, INC.
unchanged
-
-475
3,525
 -%
Apr 23, 2024
Gradient Investments LLC
reduced
-78.57
-1,531
399
 -%
Apr 23, 2024
Venturi Wealth Management, LLC
reduced
-98.74
-843,035
10,317
 -%
Apr 23, 2024
HALL LAURIE J TRUSTEE
unchanged
-
-1,000
40,000
 0.01%
Apr 23, 2024
NATIONS FINANCIAL GROUP INC, /IA/ /ADV
added
18.16
55,315
447,879
 0.04%
Apr 23, 2024
WASHINGTON TRUST Co
unchanged
-
-1,717
47,920
 -%
Apr 23, 2024
WEDGE CAPITAL MANAGEMENT L L P/NC
reduced
-83.52
-27,819,300
5,265,030
 0.09%
Apr 23, 2024
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
added
16.32
6,592
43,580
 -%
Apr 23, 2024
REGIONS FINANCIAL CORP
added
0.09
-15,256
437,266
 -%
Apr 23, 2024
Louisiana State Employees Retirement System
reduced
-4.41
-72,369
865,215
 0.02%

1–10 of 50

Are Funds Buying or Selling DGX?

Are funds buying DGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DGX
No. of Funds

Unveiling Quest Diagnostics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.07%
13,575,974
SC 13G/A
Jan 25, 2024
state street corp
4.76%
5,352,341
SC 13G/A
Jan 24, 2024
blackrock inc.
9.4%
10,578,025
SC 13G/A
Feb 09, 2023
vanguard group inc
12.27%
13,973,339
SC 13G/A
Feb 07, 2023
state street corp
5.16%
5,879,980
SC 13G/A
Jan 23, 2023
blackrock inc.
10.9%
12,391,327
SC 13G/A
Apr 08, 2022
blackrock inc.
10.7%
12,807,624
SC 13G/A
Feb 10, 2022
state street corp
5.11%
6,268,789
SC 13G
Feb 07, 2022
blackrock inc.
9.5%
11,636,382
SC 13G/A
Feb 10, 2021
vanguard group inc
10.64%
14,337,685
SC 13G/A

Recent SEC filings of Quest Diagnostics Inc

View All Filings
Date Filed Form Type Document
Apr 24, 2024
10-Q
Quarterly Report
Apr 23, 2024
8-K
Current Report
Apr 11, 2024
PX14A6G
PX14A6G
Apr 05, 2024
DEF 14A
DEF 14A
Apr 05, 2024
DEFA14A
DEFA14A
Apr 03, 2024
4
Insider Trading
Mar 28, 2024
4
Insider Trading
Mar 28, 2024
4
Insider Trading
Mar 25, 2024
PRE 14A
PRE 14A
Mar 01, 2024
4
Insider Trading

Peers (Alternatives to Quest Diagnostics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
DHR
174.4B
23.7B
 1.02% 7.91%
39.62
7.35
 -8.94% -35.72%
IDXX
41.1B
3.7B
 -6.67% 2.31%
48.61
11.22
 8.72% 24.44%
A
40.3B
6.7B
 -5.56% 5.45%
32.59
5.98
 -2.81% -6.58%
DGX
14.3B
9.3B
 6.43% -6.08%
16.85
1.54
 -3.29% 6.68%
CRL
12.3B
4.1B
 -9.86% 27.62%
25.9
2.98
 3.86% -2.39%
MEDP
11.5B
2.0B
 -1.17% 90.89%
36.88
5.87
 25.57% 21.62%
EXAS
11.5B
2.5B
 -0.82% -0.49%
-56.23
4.59
 19.93% 67.26%
NTRA
11.0B
1.1B
 0.12% 80.51%
-25.41
10.21
 31.99% 20.63%
MID-CAP
NEOG
2.7B
929.2M
 -18.50% -26.31%
1.7K
2.89
 28.93% 111.61%
GH
2.2B
563.9M
 5.66% -15.62%
-4.59
3.91
 25.45% 26.76%
SMALL-CAP
CDNA
413.2M
280.3M
 -17.90% -0.25%
-2.17
1.47
 -12.89% -148.37%
ACRS
83.0M
31.2M
 0.86% -86.93%
-0.94
2.66
 5.03% -1.81%
AWH
42.0M
9.2M
 -4.49% -35.24%
-2.51
4.58
 11.85% 44.12%
APDN
4.1M
9.0M
 -50.00% -75.76%
-0.56
0.45
 -53.31% 2.21%
BIOC
183.8K
25.9M
 -50.00% -94.83%
-0.01
0.01
 -57.78% -93.11%

Quest Diagnostics Inc News

Latest updates
MarketBeat • 9 hours ago
UBS Group Raises Quest Diagnostics (NYSE:DGX) Price Target to $146.00
Yahoo Finance UK • 15 hours ago
Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
MarketBeat • 18 hours ago
Quest Diagnostics (NYSE:DGX) Shares Gap Up to $130.09
MarketWatch • 30 hours ago
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Seeking Alpha • 32 hours ago
Quest Diagnostics rises 5% on 2024 outlook raise, quarterly results (NYSE:DGX)
Benzinga • 34 hours ago
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic Why Is Quest
Yahoo Finance • 37 hours ago
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Simply Wall St • 39 hours ago
We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
MarketWatch • 22 Apr 2024 • 09:16 pm
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Simply Wall St • 02 Apr 2024 • 07:00 am
Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares

Quest Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue3.4%2,3662,2882,2952,3382,3312,3332,4862,4532,6112,7442,7742,5502,7203,0022,7861,8271,8221,9261,9561,9531,891
Cost Of Revenue2.8%1,5951,5521,5411,5461,5601,5751,6181,6111,6461,7181,6701,5651,6261,7331,5801,2211,2701,2641,2641,2651,244
Costs and Expenses2.2%2,0662,0211,9531,9902,0262,1982,0942,0652,0982,2082,1222,0172,0602,2072,0681,5441,6471,5631,6431,6461,643
  S&GA Expenses8.1%440407380416439563464422425464427429407447396360347349362362384
EBITDA Margin-1.1%0.15*0.15*0.14*0.14*0.14*0.16*0.19*0.21*0.25*0.26*0.28*0.29*0.25*0.22*0.20*0.15*0.15*0.16*---
Interest Expenses-7.5%-43.00-40.00-40.00-37.00-35.00-32.00-33.00-36.00-37.00-37.00-38.00-38.00-38.00-39.00-42.00-41.00-41.00-42.00-44.00-45.00-44.00
Income Taxes65.0%66.0040.0068.0075.0065.00-4.0081.0077.0011011415317715319117766.0026.0072.0062.0063.0050.00
Earnings Before Taxes12.2%266237299317277109351323452502654817626758753255118328270265213
EBT Margin-1.3%0.12*0.12*0.11*0.11*0.11*0.12*0.16*0.18*0.23*0.24*0.26*0.27*0.23*0.20*0.17*0.13*0.13*0.14*---
Net Income1.0%19419222523520210125623435539050563146957956818599.00253215226164
Net Income Margin-1.3%0.09*0.09*0.08*0.08*0.08*0.10*0.12*0.14*0.18*0.18*0.20*0.20*0.17*0.15*0.13*0.10*0.10*0.11*---
Free Cashflow-89.0%50.00455102340-33.00187384326417337472376645379771273164176---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.5%13,95414,02213,48213,42512,79412,83713,22313,31213,44213,61113,57212,86113,93114,02614,14312,99012,04912,84312,01911,76011,937
  Current Assets-6.1%2,2282,3721,8151,7331,8141,8982,3342,4262,4752,7412,8542,1462,9993,0583,3482,3801,5602,4901,7791,5661,778
    Cash Equivalents-30.9%4746861431261753157007907128729875601,2301,1581,6059883421,192434273464
  Inventory-4.7%18119018418419019218318719720820519922322320515412612311210598.00
  Net PPE-0.3%1,8101,8161,8301,8141,7951,7661,7071,6641,6681,7071,6341,6221,6241,6271,5441,5051,4611,4531,3511,3071,277
  Goodwill1.3%7,8307,7337,7322677,2417,2207,1907,1957,1977,0957,0577,0456,8706,8736,8806,78993.006,619---
  Current Liabilities26.6%2,2981,8151,6181,8751,3551,5511,6021,5771,7001,7531,7591,5511,7071,7762,3891,8431,1291,9902,0111,9042,282
  Long Term Debt-13.7%3,8044,4103,9463,7773,9753,9783,9803,9833,9854,0104,0064,0084,0104,0134,0184,0204,0333,9663,1883,1693,131
    LT Debt, Current199.0%9063033045182.002.002.002.002.002.001.002.002.002.005555553.00804---
Shareholder's Equity2.6%6,4696,3076,4256,2876,0885,8936,2726,4506,4156,4836,4325,9406,7906,8096,4465,8815,7035,6875,6545,5095,341
  Retained Earnings1.2%8,9358,8258,7118,5668,4128,2908,2638,0837,9267,6497,33310,2469,6909,3038,8008,3078,1978,1747,9927,8497,694
  Additional Paid-In Capital-1.2%2,2922,3202,3022,2842,2662,2952,2722,2502,2262,2601,9362,5552,8242,8412,8012,7642,7382,7222,7052,6862,671
Shares Outstanding-111-112112112-116118119-127125133-135134134-135134134
Minority Interest5.7%37.0035.0038.0038.0038.0037.0037.0039.0038.0039.0040.0041.0045.0050.0046.0050.0046.0046.0049.0050.0051.00
Float----15,700---15,400---16,100---15,200---13,700-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-70.8%15452720744494.00334502402480481561460731541862355247348299321275
  Share Based Compensation15.8%22.0019.0018.0016.0024.0022.0018.0019.0018.0019.0021.0021.0018.0034.0032.0017.0014.0012.0012.0015.0017.00
Cashflow From Investing-86.8%-213-114-107-682-158-174-118-82.00-169-227-96.00437-93.00-168-193-205-206-100-109-92.00-110
Cashflow From Financing-217.7%-153130-83.00189-76.00-545-474-242-471-369-38.00-1,567-566-820-52.00496-891510-29.00-420164
  Dividend Payments-1.2%79.0080.0080.0080.0074.0075.0078.0078.0074.0077.0076.0081.0075.0075.0076.0075.0071.0071.0072.0071.0072.00
  Buy Backs-100.0%-275---461374200373289-1,500410250--75.0020050.0050.0053.00

DGX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net revenues$ 9,252$ 9,883$ 10,788
Operating costs and expenses and other operating income:   
Cost of services6,1996,4506,579
Selling, general and administrative1,6421,8741,727
Amortization of intangible assets108120103
Other operating expense (income), net4111(2)
Total operating costs and expenses, net7,9908,4558,407
Operating income1,2621,4282,381
Other income (expense):   
Interest expense, net(152)(138)(151)
Other income (expense), net20(55)369
Total non-operating (expense) income, net(132)(193)218
Income before income taxes and equity in earnings of equity method investees1,1301,2352,599
Income tax expense(248)(264)(597)
Equity in earnings of equity method investees, net of taxes264478
Net income9081,0152,080
Less: Net income attributable to noncontrolling interests546985
Net income attributable to Quest Diagnostics$ 854$ 946$ 1,995
Earnings per share attributable to Quest Diagnostics’ common stockholders:   
Basic (in dollars per share)$ 7.59$ 8.10$ 15.85
Diluted (in dollars per share)$ 7.49$ 7.97$ 15.55

DGX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
shares in Millions, $ in Millions
Dec. 31, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 686$ 315
Accounts receivable, net of allowance for credit losses of $27 and $30 as of December 31, 2023 and 2022, respectively1,2101,195
Inventories190192
Prepaid expenses and other current assets286196
Total current assets2,3721,898
Property, plant and equipment, net1,8161,766
Operating lease right-of-use assets602585
Goodwill7,7337,220
Intangible assets, net1,1661,092
Investments in equity method investees135132
Other assets198144
Total assets14,02212,837
Liabilities and Stockholders' Equity  
Accounts payable and accrued expenses1,3591,396
Less: Current portion of long-term debt3032
Current portion of long-term operating lease liabilities153153
Total current liabilities1,8151,551
Long-term debt4,4103,978
Long-term operating lease liabilities503489
Other liabilities876812
Commitments and contingencies
Redeemable noncontrolling interest7677
Quest Diagnostics stockholders’ equity:  
Common stock, par value $0.01 per share; 600 shares authorized as of both December 31, 2023 and 2022; 162 shares issued as of both December 31, 2023 and 202222
Additional paid-in capital2,3202,295
Retained earnings8,8258,290
Accumulated other comprehensive (loss) income(14)(21)
Treasury stock, at cost; 51 shares as of both December 31, 2023 and 2022(4,826)(4,673)
Total Quest Diagnostics stockholders' equity6,3075,893
Noncontrolling interests3537
Total stockholders' equity6,3425,930
Total liabilities and stockholders' equity$ 14,022$ 12,837
Common stock, shares issued162162

About Quest Diagnostics Inc

DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
 CEO
 WEBSITEquestdiagnostics.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES40000

Quest Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Quest Diagnostics Inc? What does DGX stand for in stocks?

DGX is the stock ticker symbol of Quest Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quest Diagnostics Inc (DGX)?

As of Wed Apr 24 2024, market cap of Quest Diagnostics Inc is 15.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers. The fair value of Quest Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quest Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quest Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether DGX is over valued or under valued. Whether Quest Diagnostics Inc is cheap or expensive depends on the assumptions which impact Quest Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DGX.

What is Quest Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, DGX's PE ratio (Price to Earnings) is 17.84 and Price to Sales (PS) ratio is 1.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Quest Diagnostics Inc's stock?

In the past 10 years, Quest Diagnostics Inc has provided 0.113 (multiply by 100 for percentage) rate of return.